June 22, 2026
Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about its Alzheimer's drug research, a deal that could be upended if the court's class certification order is reversed on appeal.
August 13, 2025
Investors accusing Cassava Sciences Inc. of inflating its stock price with manipulated research data of its Alzheimer's drug can proceed with their claims as a class, with the court finding the suit's named plaintiffs are adequate representatives despite Cassava's claims they were only "out to make a quick buck."
January 20, 2022
Texas-based biotechnology company Cassava Sciences Inc. has oversold to the public and the U.S. Food and Drug Administration the efficacy of its two products that can allegedly detect signs of Alzheimer's disease and treat it, according to a slew of class actions filed in the Lone Star State.